White House Budget Office Approves Plan to Rescind Controversial Trump-Era Insulin Rule
Earlier this week, the White House Office of Management and Budget (OMB) completed its review of HHS’ proposal to rescind the Trump Administration’s final
Tennessee Governor Enacts Law to Protect 340B Covered Entities from Discriminatory Reimbursement Practices
Last week, Tennessee Governor Bill Lee signed into a law a bill that will protect 340B covered entities and their contract pharmacies from discriminatory
340B ‘Instrumental’ in Family Health Center of Kalamazoo Vaccinating Community
Family Health Centers of Kalamazoo in Kalamazoo, Michigan has been busy these past few months running back-to-back COVID-19 vaccine clinics. As of last
CV340B’s Northeast Regional Advocacy Plans ‘340B in the Northeast’ Webinar for May 25th, 2021
CV340B’s Northeast Regional Advocacy Group is hosting a webinar titled ‘340B in the Northeast’ scheduled for 11:00am- 12:00pm on Tuesday
HRSA Determines Six Manufacturers’ Contract Pharmacy Policies Violate 340B Statute
Yesterday, HRSA Acting Administrator Diana Espinosa sent letters to Eli Lilly, AstraZeneca, Novartis, Novo Nordisk, Sanofi, and United Therapeutics making
340B providers filed an amicus brief in opposition to AstraZeneca’s motion to invalidate Advisory Opinion.
On May 4, 2021, 340B safety-net providers and their trade associations filed a brief in the case brought by AstraZeneca Pharmaceuticals LP (AstraZeneca)
Arkansas Passes Comprehensive 340B Anti-Discriminatory Reimbursement Bill, Protects Covered Entities Rights to Use Contract Pharmacies
Last week, Arkansas passed legislation (HB 1881) intended to address 340B discriminatory pricing practices by third party payers and pharmacy benefit
Indiana General Assembly passes landmark 340B anti-discrimination bill (HB 1405)
On April 22, 2021, the Indiana General Assembly passed a bill (HB 1405) that protects Indiana 340B safety-net providers from discriminatory and predatory
United Therapeutics Announces Details on Phase Two of its Restrict Contract Pharmacy Policy
By letter dated April 12, drug manufacturer United Therapeutics (UT) announced additional details regarding the second phase of its restrictive contract
Gilead Delays Harmful Changes to Patient Assistance Program Until January 1, 2022
Last week, Gilead issued a statement that it is delaying a change to its Advancing Access® Patient Assistance/Medication Assistance Program (PAP/MAP) until